Transaction · 0001817160-26-000023
NRIXNurix Therapeutics, Inc.
Hansen Gwenn
Hansen Gwenn, CSO, reported a transaction classified as exercise at Nurix Therapeutics, Inc. involving 3573.000000 shares for an estimated $0.00. Reported holdings after the transaction were 35730.000000 shares. The stored filing text includes a detected 10b5-1 reference.
exerciseSEC transaction code MCSO
- Trade date
- Oct 30, 2026
- Filing date
- Nov 03, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
NRIX price since this filing
Daily closing prices, with the filing date and available return windowsNRIX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -7.7%1w ago -1.4%1d ago +5.5%
Returns since7d30d90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001817160-26-000023 Restricted Stock Units
- Transaction date
- Oct 30, 2026 Filed Nov 03, 2026, 12:42 AM · 4d delay
- Shares
- 3,573 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 35,730 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership 10b5-1 Detected
Filing-only score
-20 points
Compact filing score computed from stored Form 4 facts. Version v1.
Low filing signal
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
Chief Scientific Officer
Officer YesDirector No10% NoOther No
Footnotes & amended
- F1
The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). T…
- F2
Represents the weighted average sale price. The lowest price at which shares were sold was $26.135 and the highest price at which shares were sold was $26.42. The Reporting Person undertakes to provid…
- F3
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- F4
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F5
The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the…
- F6
RSUs do not expire; they either vest or are canceled prior to the vest date.
- F7
The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the…
- F8
The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the…
- F9
The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.
Related transactions
Same SEC filing0 other transactions
Recent company activity
NRIX0 recent txs